



Special Article



Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach




Special Article



Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach

NEOADJUVANT THERAPY

Statement 15. Neoadjuvant chemotherapy for potentially resectable gastric cancer **is not conclusive if** D2 LND is considered (evidence: **high**, recommendation: inconclusive).



In conclusion, addition of neoadjuvant DOS to D2 gastrectomy and adjuvant S-1 led to significant **tumor downstaging** and **improved PFS** with **acceptable safety** in the PRODIGY study. These results suggest that this strategy **should be considered a standard treatment** for patients in Asia with resectable advanced gastric or gastroesophageal cancer. Importantly, the results of PRODIGY support one common treatment strategy—perioperative chemotherapy with surgery—for patients with LAGC in East Asia as well as in the West.